INTERIM RESULTS OF A DOUBLE-BLIND, RANDOMIZED PHASE 2 STUDY OF THE SAFETY OF TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE PLUS TENOFOVIR DISOPROXIL FUMARATE, AND ENTECAVIR IN THE TREATMENT OF CHRONIC HEPATITIS B SUBJECTS WITH DECOMPENSATED LIVER DISEASE

Liaw, Yun-FanLee, Chuan-MoAkarca, Ulus S.George, Papatheodoridis V.Wong, FlorenceChang, Ting-TsungHorban, AndrzejWang, Chia C.Kwan, PeterButi, MariaPrieto, MartinBerg, ThomasKitrinos, Kathryn M.Sorbel, JeffMondou, ElsaFrederick, DavidRousseau, FranckSchiff, Eugene R.2019-10-272019-10-2720090270-9139https://hdl.handle.net/11454/4279560th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases -- OCT 30-NOV 03, 2009 -- Boston, MAeninfo:eu-repo/semantics/closedAccessINTERIM RESULTS OF A DOUBLE-BLIND, RANDOMIZED PHASE 2 STUDY OF THE SAFETY OF TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE PLUS TENOFOVIR DISOPROXIL FUMARATE, AND ENTECAVIR IN THE TREATMENT OF CHRONIC HEPATITIS B SUBJECTS WITH DECOMPENSATED LIVER DISEASEConference Object504409A410AWOS:000270456000223Q1